

EXECUTIVE PRIVILEGED AND CONFIDENTIAL

September XX, 2021

Dear Colleague:

We are writing to ensure that you have the critical information needed regarding monoclonal antibodies (mAb) and are proactively providing this treatment to individuals with or exposed to COVID-19.

Monoclonal antibodies are a critical tool in the battle against COVID-19 and are effective against variants, including the highly contagious Delta variant. Currently, the Federal Food and Drug Administration (FDA) has authorized three mAb products under Emergency Use Authorization (EUA):

1. [Bamlanivimab and Etesevimab](#), an Intravenous Infusion to treat mild to moderate COVID-19 infection in individuals who are at high risk for progressing to severe COVID-19 or as a post-exposure prophylaxis for unvaccinated or immunocompromised individuals who are high risk for progression to severe COVID-19;
2. [REGEN-COV](#) Casirivimab and Imdevimab, an Intravenous Infusion or Subcutaneous Injection to treat mild to moderate COVID-19 infection in individuals who are at high risk for progressing to severe COVID-19 or as a post-exposure prophylaxis for unvaccinated or immunocompromised individuals who are high risk for progression to severe COVID-19; and
3. [Sotrovimab](#)¹, an Intravenous Infusion to treat mild to moderate COVID-19 infection in individuals who are at high risk for progressing to severe COVID-19

Maryland currently has sufficient quantities of mAb at no cost to providers and patients. We strongly encourage you to offer these critical mAb to patients upon request or prescribe them accordingly. If you are not a mAb provider and are interested in becoming one, reach out to mdhpp.dhmm@maryland.gov.

There are 80 facilities across Maryland that are authorized to provide mAb in an out-patient setting. To refer a patient, please use the CRISP platform [eReferral Tool](#) or the Maryland Department of Health (MDH) [Maryland Referral Form](#). MDH also has a variety of [Provider Resources](#) related to mAb for further information.

Again, we strongly urge you to proactively use this effective, critical treatment and greatly appreciate the role you are playing in Maryland's fight against COVID-19.

Sincerely,

Gene Ransom

¹ Sotrovimab is only commercially available at this time and not provided via Federal direct ordering.